// App-Quantinova.ai

THU0330 : EFFECTS OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED ILD (SSC-ILD) AND DIFFERING EXTENTS OF SKIN FIBROSIS: FURTHER ANALYSES OF THE SENSCIS TRIAL

Researchers

Presenter

  • Y. Allanore

Principal Investigators

  • V. Steen

  • M. Kuwana

  • C. Denton

  • M. Matucci-Cerinic

  • E. Volkmann

  • D. Khanna

  • D. Wachtlin

  • M. Gahlemann

  • M. Quaresma

  • M. Alves

  • O. Distler

Medical Centers

  • Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France

  • Division of Hematology, MedStar Georgetown University Hospital,Washington DC,Vereinigte Staaten

  • Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

  • University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom

  • University of Florence, Department of Health Sciences, Florence, Italy

  • Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, California, United States of America

  • Department of Radiology, University of Michigan, Ann Arbor, United States of America

  • Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany

  • Boehringer Ingelheim (Schweiz), GmbH, Basel, Switzerland,

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Department of Neurology, University Hospital Zurich, Zurich, Switzerland

Locations

  • France

  • United States

  • Japan

  • United Kingdom

  • Italy

  • Germany

  • Switzerland

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Scleroderma

  • Mental retardation, X-linked, syndromic, 15

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Inventiva

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved